Details of the Drug

General Information of Drug (ID: DM5HO2X)

Drug Name

Ponsegromab

Synonyms

PF-06946860

Indication

Disease Entry	ICD 11	Status	REF
Cancer cachexia	MG20.0	Phase 2	[1]
Heart failure	BD10-BD13	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth/differentiation factor 15 (GDF15)	TT4MXVG	GDF15_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05546476) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05492500) A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE. U.S.National Institutes of Health.
3	Current advancements in pharmacotherapy for cancer cachexia. Expert Opin Pharmacother. 2023 Apr;24(5):629-639.